Schering’s imaging sales fall

Article

Revenues in Schering’s diagnostics business unit fell 6% in 1998, the German contrast agent developer reported last month. The Berlin-based company attributed the fall primarily to exchange-rate effects, while falling contrast media prices also had

Revenues in Schering’s diagnostics business unit fell 6% in 1998, the German contrast agent developer reported last month. The Berlin-based company attributed the fall primarily to exchange-rate effects, while falling contrast media prices also had an impact. Diagnostics sales fell particularly hard in the fourth quarter, the company said.

For the year (end-December), Schering posted imaging sales of DM 1.48 billion ($837.5 million), compared with DM 1.58 billion ($892.4 million) in 1997. Of total sales last year, x-ray contrast media accounted for DM 1.08 billion ($613.4 million), while MRI contrast sales totaled DM 388 million ($219.6 million). For the entire company, Schering reported that sales climbed 3% before exchange-rate adjustments to DM 6.42 billion ($3.64 billion), and the company reported 7% growth in net income, to DM 478 million ($270.5 million).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.